|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MSH6 overexpression could be a marker of aggressiveness in PrCa.
|
31209634 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this article is to provide a review of principles of genetic testing in prostate cancer and highlight the significance of clinical genetic testing of BRCA1/2 and other genes (CHEK2, HOXB13, PALB2), including Lynch syndrome genes (MLH1, MSH2, MSH6, and PMS2) in men with metastatic prostate cancer.
|
30681994 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify prostate cancers with MSI, 316 advanced prostate cancers were analyzed by immunohistochemistry (IHC) for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6 on a TMA format.
|
31811435 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of germline mutations in DNA damage repair genes ( BRCA1, BRCA2, CHEK2, ATM and PALB2) and in DNA mismatch repair genes ( MLH1, MSH2, MSH6 and PMS2) can drive the development of prostate cancer.
|
30730411 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
|
27803051 |
2017 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report 8 additional genes with suggestive evidence of association, including the DNA repair genes PARP2 and MSH6 Finally, we observed an excess of rare truncation variants in 5 genes, including the DNA repair genes MSH6, BRCA1, and BRCA2 This adds to the growing body of evidence that DNA repair pathway defects may influence susceptibility to aggressive prostate cancer.
|
27486019 |
2016 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
|
25255306 |
2014 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancers (mean age at diagnosis = 62 ± SD = 8 years) from 32 MMR mutation carriers (23 MSH2, 5 MLH1 and 4 MSH6) enrolled in the Australasian, Mayo Clinic and Ontario sites of the Colon Cancer Family Registry were examined for clinico-pathologic features and MMR-deficiency (immunohistochemical loss of MMR protein expression and high levels of microsatellite instability; MSI-H).
|
25117503 |
2014 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy.
|
23559371 |
2013 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that mismatch repair gene polymorphism could be a risk factor for prostate cancer and p53 Pro/Pro genotype carriers could influence MSH3 and MSH6 polymorphisms.
|
18355840 |
2008 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although the vast majority of AR mutations appeared capable of increased activation in response to ART-27, an AR mutation identified in prostate cancer (AR P340L) and AIS (AR E2K) show reduced transcriptional responses to ART-27, whereas their response to the p160 class of coactivators was not diminished.
|
15919721 |
2005 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MMR-related genes (hMLH1, hPMS1, hPMS2, hMSH2, hMSH3, hMSH6) showed mRNA transcripts in all prostate cancer cell lines.
|
11444857 |
2001 |